IBI354 Clinical Trials

3 actively recruiting trials

▼ -1 trial since August 2026

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.1
Innovent Biologics (Suzhou) Co. Ltd.1
Fudan University1

Indications

Cancer3
HER2-positive Breast Cancer2
Breast Cancer2
Hormone Receptor Negative Tumor1
Locally Advanced (Unresectable) or Metastatic Solid Tumors1

Other3 trials

A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Phase 1/2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase 2

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.